Nasdaq

Pfizer to Reimburse BioNTech for COVID Vaccine Royalty Settlements

BioNTech (BNTX) has reached settlement agreements with the U.S. National Institutes of Health (NIH) and the University of Pennsylvania over royalties tied to its COVID-19 vaccine, resolving disputes ...

BioNTech COVID-19 vaccines coming to Taiwan, Chinese agent says

TAIPEI -The Chinese sales agent for Germany's BioNTech SE said on Sunday it had signed a deal to provide 10 million COVID-19 ...

German vaccine maker BioNTech to cut up to 1,860 jobs, close plants

German vaccine manufacturer BioNTech, which rose to global prominence with its Covid-19 vaccine developed alongside Pfizer, plans to close several production sites, with up to 1,860 jobs affected. The ...

BioNTech’s Costly Pivot: Cancer Pipeline Promises Meet Political and Financial Realities

The company’s financial buffer remains formidable: €16.76 billion in cash and marketable securities. Yet even as BioNTech pours money into its cancer programs, it is simultaneously slimming down its ...
Benzinga.com

Moderna And BioNTech Bet On Personalized Cancer Vaccines To Revive Fortunes After Dwindling COVID-19 Vaccine Sales

BioNTech SE (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are making strides in personalized cancer vaccines, leveraging the mRNA technology instrumental during the COVID-19 pandemic. Also Read: FDA ...
Nasdaq

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
Business Wire

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
MM&M

BioNTech, Regeneron tout mRNA cancer vaccine’s Phase 2 trial results

A combination mRNA cancer vaccine from BioNTech and Regeneron may be one step closer to actualization based on initial Phase 2 results unveiled Tuesday. The mRNA-based vaccine, BNT111, in combination ...
Health Affairs

COVID-19 Vaccines: Moderna And Pfizer-BioNTech Use Varied By Urban, Rural Counties

We investigated county-level variation in mRNA COVID-19 vaccine use among Medicare beneficiaries throughout the United States. There was greater use of Pfizer-BioNTech vaccines than Moderna vaccines ...

Opportunities in the oncology market: Positioning for the next billion-dollar catalyst with BioNTech, Vidac Pharma, and Pfizer

Large Pipeline The first-quarter figures were sobering. BioNTech generated revenue of just EUR 118.1 million, a decline of ...
JD Supra

BioNTech Sues Moderna over mRNA Vaccine Technology

One of the paradoxically beneficial consequences of the COVID pandemic was that even without the compulsory aspects of the vaccine patent waiver proposed by certain WTO member states (Brazil, India, ...